State of art and advances on the treatment of bone metastases from breast cancer: a concise review

被引：14
作者：
Rossi, Lorenzo [1 ,2 ]
Longhitano, Claudio [1 ,2 ]
Kola, Florenc [3 ]
Del Grande, Maria [1 ]
机构：
[1] Inst Oncol Southern Switzerland IOSI, Bellinzona, Switzerland
[2] Breast Unit Southern Switzerland CSSI, Lugano, Switzerland
[3] Ente Osped Cantonale, Dept Internal Med, Bellinzona, Switzerland
来源：
CHINESE CLINICAL ONCOLOGY | 2020年 / 9卷 / 02期
关键词：
Breast cancer (BC); bone metastases; bisphosphonates; denosumab; biomarkers; SKELETAL-RELATED EVENTS; ZOLEDRONIC ACID; ANTITUMOR-ACTIVITY; PAIN PALLIATION; POSTMENOPAUSAL WOMEN; ADJUVANT TREATMENT; IMPROVED SURVIVAL; ORAL CLODRONATE; SOLID TUMORS; DOUBLE-BLIND;
D O I：
10.21037/cco.2020.01.07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Bone is one of the most common metastatic sites in metastatic breast cancer (mBC). The presence of bone metastases can lead to various complications including pain, spinal cord compression, hypercalcaemia, pathological fractures. The treatment of bone metastases of breast cancer (BC) is mainly based on the biological characteristics of the primary tumour, but there are also specific treatments for bone lesions including bone modifiers, radionuclides, or localized treatments such as radiotherapy, surgery or vertebroplasty. In this review, we analyse the state of art of the common treatments and the advances of bone metastases of BC. Finally, we summarize the state of art of biomarkers in diagnosis, prognosis and prediction to therapy.
引用
收藏
页数：11
相关论文
共 86 条
  • [1] Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
    Amadori, Dino
    Aglietta, Massimo
    Alessi, Barbara
    Gianni, Lorenzo
    Ibrahim, Toni
    Farina, Gabriella
    Gaion, Fernando
    Bertoldo, Francesco
    Santini, Daniele
    Rondena, Roberta
    Bogani, Paola
    Ripamonti, Carla I.
    [J]. LANCET ONCOLOGY, 2013, 14 (07) : 663 - 670
  • [2] Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis
    Anastasilakis, A. D.
    Toulis, K. A.
    Goulis, D. G.
    Polyzos, S. A.
    Delaroudis, S.
    Giomisi, A.
    Terpos, E.
    [J]. HORMONE AND METABOLIC RESEARCH, 2009, 41 (10) : 721 - 729
  • [3] [Anonymous], 2017, COCHRANE DB SYST REV
  • [4] [Anonymous], Breast Cancer. Version 5.2021 - 2021
  • [5] Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer
    Bayet-Robert, Mathilde
    Kwiatkowski, Fabrice
    Leheurteur, Marianne
    Gachon, Francoise
    Planchat, Eloise
    Abrial, Catherine
    Mouret-Reynier, Marie-Ange
    Durando, Xavier
    Barthomeuf, Chantal
    Chollet, Philippe
    [J]. CANCER BIOLOGY & THERAPY, 2010, 9 (01) : 8 - 14
  • [6] The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone
    Bellanger, Aurelie
    Donini, Caterina F.
    Vendrell, Julie A.
    Lavaud, Jonathan
    Machuca-Gayet, Irma
    Ruel, Maeva
    Vollaire, Julien
    Grisard, Evelyne
    Gyorffy, Balazs
    Bieche, Ivan
    Peyruchaud, Olivier
    Coll, Jean-Luc
    Treilleux, Isabelle
    Maguer-Satta, Veronique
    Josserand, Veronique
    Cohen, Pascale A.
    [J]. JOURNAL OF PATHOLOGY, 2017, 242 (01) : 73 - 89
  • [7] Prognostic factors for skeletal complications from metastatic bone disease in breast cancer
    Brown, Janet E.
    Cook, Richard J.
    Lipton, Allan
    Costa, Luis
    Coleman, Robert E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (03) : 767 - 779
  • [8] Zoledronic Acid Effectively Prevents Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results
    Brufsky, Adam M.
    Bosserman, Linda D.
    Caradonna, Richard R.
    Haley, Barbara B.
    Jones, Michael
    Moore, Halle C. F.
    Jin, Lixian
    Warsi, Ghulam M.
    Ericson, Solveig G.
    Perez, Edith A.
    [J]. CLINICAL BREAST CANCER, 2009, 9 (02) : 77 - 85
  • [9] 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
    Cardoso, F.
    Senkus, E.
    Costa, A.
    Papadopoulos, E.
    Aapro, M.
    Andre, F.
    Harbeck, N.
    Aguilar Lopez, B.
    Barrios, C. H.
    Bergh, J.
    Biganzoli, L.
    Boers-Doers, C. B.
    Cardoso, M. J.
    Carey, L. A.
    Cortes, J.
    Curigliano, G.
    Dieras, V.
    El Saghir, N. S.
    Eniu, A.
    Fallowfield, L.
    Francis, P. A.
    Gelmon, K.
    Johnston, S. R. D.
    Kaufmann, B.
    Koppikar, S.
    Krop, I. E.
    Mayer, M.
    Nakigudde, G.
    Offersen, B. V.
    Ohno, S.
    Pagani, O.
    Paluch-Shimon, S.
    Penault-Llorca, F.
    Prat, A.
    Rugo, H. S.
    Sledge, G. W.
    Spence, D.
    Thomssen, C.
    Vorobiof, D. A.
    Xu, B.
    Norton, L.
    Winer, E. P.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (08) : 1634 - 1657
  • [10] Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class
    Clezardin, Philippe
    [J]. BONE, 2011, 48 (01) : 71 - 79
123456789